Pathological aspects on Parkinson's syndrome.
D000818:Animals; D001479:Basal Ganglia / Q000503:physiopathology*; D001480:Basal Ganglia Diseases / Q000503:physiopathology; D002490:Central Nervous System / Q000187:drug effects / Q000503:physiopathology; D002746:Chlorpromazine / Q000009:adverse effects / Q000494:pharmacology; D003342:Corpus Striatum / Q000503:physiopathology; D003864:Depression, Chemical; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D006801:Humans; D008722:Methods; D009046:Motor Neurons / Q000503:physiopathology*; D009069:Movement Disorders / Q000139:chemically induced / Q000503:physiopathology*; D009127:Muscle Rigidity / Q000503:physiopathology; D009470:Muscle Spindles / Q000503:physiopathology*; D009410:Nerve Degeneration / Q000187:drug effects; D009420:Nervous System / Q000503:physiopathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology*; D051381:Rats; D012110:Reserpine / Q000009:adverse effects / Q000494:pharmacology; D013378:Substantia Nigra / Q000503:physiopathology*
D004295:Dihydroxyphenylalanine; D012110:Reserpine; D002746:Chlorpromazine